TUDCA is also being used in a phase 2 clinical trial for treating juvenile diabetes (NCT02218619), has been shown to improve insulin sensitivity in obese people30 and could be used for treating primary biliary cirrhosis or PBC31. Here, INS is linked to type 1 diabetes mellitus.